Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPz Cussons Regulatory News (PZC)

Share Price Information for Pz Cussons (PZC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 104.00
Bid: 103.20
Ask: 104.00
Change: 2.40 (2.36%)
Spread: 0.80 (0.775%)
Open: 101.00
High: 104.00
Low: 101.00
Prev. Close: 101.60
PZC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update for the Third Quarter 2020

16 Apr 2020 07:00

RNS Number : 8020J
PZ CUSSONS PLC
16 April 2020
 

16th April 2020

PZ Cussons Plc

 

("PZ Cussons" or the "Group")

 

Trading Update for the Third Quarter 2020

 

PZ Cussons Plc, a leading international consumer products group, today updates on its trading during the third quarter 2020, ended 29th February 2020 ('Q3' or 'the quarter').

Headlines

 

· Continued progress on the implementation of the Group strategy.

o Focus Brand revenue in Q3 grew compared to last year, driven by Cussons Baby, Morning Fresh, a return to growth for Carex and good performance of Electricals

o Completion of the sale of local Polish brand Luksja and announcement of disposal of Nutricima in Nigeria.

o Appointment of new CEO, Jonathan Myers, starting 1st May.

· Overall revenue in the quarter declined against last year, albeit at a reduced rate compared to the first half of the year.

· Key markets continued to be impacted by consumer fragility, and towards the end of the period, the start of Covid-19 pandemic. 

· Balance sheet remained strong, with net debt of £116m versus £183m at the same time last year, and headroom of £147m under our committed bank facilities. Continued focus on management actions to manage liquidity across the Group. 

· Impact of Covid-19 continues to be significant, although varies depending on business unit and market.

· Our full year profit guidance remains within consensus range, albeit at the lower end.

 

Q3 Regional Revenue Performance

 

In Europe & the Americas, there was some improvement in UK personal care with the rate of decline in the quarter softening compared to the first half of the year. Carex benefitted from a significant increase in demand towards the end of the quarter driven by the Covid-19 pandemic. Our Beauty category faced tough competitive conditions in the UK in particular, resulting in a decline in revenue for the quarter compared to last year.

 

In Asia Pacific, continued good growth in Indonesia in the quarter versus last year was offset by increased promotional spend and competitor activities in Australia, mainly across the Food and Beauty categories. 

 

In Africa, revenue declined overall in Q3 compared to last year. Continued growth in Electricals and in selected premium brands was impacted by continued decline in our value brands in Home and Personal Care.

 

Impact of COVID-19

 

Our People and Wider Role in Society

 

Our people, whether working from home or keeping our factories around the globe running, have responded fantastically to the challenges facing us. Protecting them whilst continuing to produce products that can genuinely help stop the spread of Covid-19 remains our priority. The innovation, rapid product development and response to unprecedented conditions shown by our teams has been outstanding, and underlines both the scale of the challenges facing us, and the strength of our brands and teams. 

 

Our key manufacturing sites across all regions remain open, with our employees demonstrating huge commitment to ensuring that production of our important hygiene products continues. Where possible, all employees who can work from home are doing so, although each of our markets requires a different approach to this. Ensuring safe and secure conditions for those who still need to come to a place of work continues to be a priority.

 

We are also conscious of our wider role in society and will continue to support those most at risk in our communities. Our approach varies from market to market but we have programmes in place to distribute free soap, sanitiser and hand wash to those most vulnerable and in need. For example, in the UK, our "That's why we Carex" programme is working with the homeless, elderly and other vulnerable groups. In Nigeria, the PZ Cussons Foundation is distributing soap in the north of the country while in Asia we support those communities close to our manufacturing sites.

 

Trading Implications

 

The impact of Covid-19 across our businesses is significant, although very different across business unit and market.

 

In the UK, we are experiencing exceptionally high demand for our Carex hand wash and sanitiser gel products and Imperial Leather soap. Our focus remains on sourcing, producing and distributing these. Our team has shown exceptional ability to reconfigure products and supply chains rapidly, but we continue to face challenges in sourcing packaging and raw materials to enable us to fully meet demand.

 

Our Beauty business has been severely impacted. St Tropez has been hit hard by the social distancing measures in place in the UK, US and across Europe. Our significant marketing activities planned for Q4 have been cancelled and we expect this business to be slow to recover. Our other beauty brands have also been adversely impacted with the focus of retailers at this time on hygiene and personal care and the closure of hair salons.

 

In Asia, our Indonesian business has continued to trade largely as normal with increased customer demand for our hygiene related products offsetting a reduction in some of our lotions and creams. Australia has seen a recent spike in demand for Morning Fresh and Raffertys Garden as a result of Covid-19 but also a severe reduction in Beauty sales.

 

The situation in Nigeria is uncertain. The recent fall in the global oil price has led to further economic pressure, and the Covid-19 situation continues to develop. All our Nigerian businesses are likely to be impacted by the significant disruption to both manufacturing and route to market. 

 

Liquidity

 

The Group has historically maintained a prudent financial position, and we entered the current crisis with a strong balance sheet.

 

PZ Cussons' external funding is through a syndicated borrowing facility which is provided by a syndicate of six lenders in the form of a £325 million committed multi-currency revolving credit facility committed until 28 November 2023. As at 29th February 2020, we had headroom of £147m under our committed facilities.

 

We continue to focus on management actions to manage liquidity carefully across the group. Recent actions taken have included the cancellation of capital expenditure projects, the review of the cost base, particularly in those areas of the business most impacted by Covid-19 and working capital initiatives across our business. At this time, we have not elected to participate in the UK furlough scheme or similar schemes in other countries.

 

We completed the sale of local Polish brand Luksja for £9.2m in the quarter and recently announced the disposal of Nutricima, our Nigerian milk business, for $20.3m. Our target debt level for the year-end remains at £110m in line with guidance at the half year.

 

Outlook

 

Whilst there is a high level of uncertainty regarding the full impact of Covid-19 across all of our different businesses and markets continues, at this point our guidance on profit remains within consensus, albeit at the lower end.

 

Given the current uncertain environment, we plan to issue our preliminary results for the year ended 31st May 2020 in late summer, with a date to be confirmed in due course.

 

- Ends -

 

Press enquiries

 

PZ Cussons

Alan Bergin (Interim Chief Financial Officer)

 

 

0161 435 1236

Instinctif Partners

Tim Linacre / Guy Scarborough

 

07949 939 237 / 07917 178 920

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTDELFFBZLFBBV
Date   Source Headline
24th Apr 20247:00 amRNSQ3 Trading and update on strategic actions
19th Apr 20248:49 amRNSDirector/PDMR Shareholding
12th Apr 202411:04 amRNSDirector/PDMR Shareholding
8th Apr 20245:29 pmRNSDirector/PDMR Shareholding
19th Mar 202410:30 amRNSDirector/PDMR Shareholding
23rd Feb 20243:47 pmRNSDirector/PDMR Shareholding
19th Feb 20243:18 pmRNSDirector/PDMR Shareholding
8th Feb 20243:40 pmRNSDirector/PDMR Shareholding
8th Feb 20243:09 pmRNSDirector/PDMR Shareholding
8th Feb 20243:07 pmRNSDirector/PDMR Shareholding
7th Feb 20247:00 amRNS2024 Interim Results
19th Jan 202410:50 amRNSDirector/PDMR Shareholding
15th Jan 20247:00 amRNSDirectorate Change
18th Dec 20233:10 pmRNSDirector/PDMR Shareholding
4th Dec 20233:03 pmRNSDirector/PDMR Shareholding
4th Dec 20237:00 amRNSDirectorate Change
29th Nov 202312:10 pmRNSDirector/PDMR Shareholding
29th Nov 202312:08 pmRNSDirector/PDMR Shareholding
23rd Nov 20235:57 pmRNSResult of AGM
23rd Nov 20237:00 amRNSAGM Trading Statement
20th Nov 20231:58 pmRNSDirector/PDMR Shareholding
19th Oct 202310:00 amRNSDirector/PDMR Shareholding
10th Oct 202311:10 amRNSDirector/PDMR Shareholding
5th Oct 20233:44 pmRNSHolding(s) in Company
27th Sep 202310:00 amRNSPreliminary Results - Correction
26th Sep 20237:00 amRNSPZ Cussons Preliminary Results
20th Sep 202311:09 amRNSDirector/PDMR Shareholding
5th Sep 20237:00 amRNSAcquisition of minority ownership of PZCN Plc
21st Aug 20232:07 pmRNSDirector/PDMR Shareholding
26th Jul 20239:22 amRNSDirector/PDMR Shareholding
19th Jul 202310:23 amRNSDirector/PDMR Shareholding
11th Jul 20232:06 pmRNSDirector/PDMR Shareholding
4th Jul 20237:00 amRNSCapital Markets Event
30th Jun 20232:18 pmRNSDirector/PDMR Shareholding
29th Jun 202311:06 amRNSDirector/PDMR Shareholding
27th Jun 20237:00 amRNSTrading Statement
21st Jun 20239:59 amRNSDirector/PDMR Shareholding
16th Jun 20237:00 amRNSDirectorate Change
19th May 20239:27 amRNSDirector/PDMR Shareholding
21st Apr 20239:00 amRNSIntention to Conduct Audit Tender
19th Apr 202310:01 amRNSDirector/PDMR Shareholding
13th Apr 20233:18 pmRNSHolding(s) in Company
13th Apr 20237:00 amRNSQ3 Trading Update
12th Apr 20232:18 pmRNSDirector/PDMR Shareholding
24th Mar 20237:00 amRNSDirectorate Change
21st Mar 20239:30 amRNSDirector/PDMR Shareholding
17th Mar 20234:35 pmRNSPrice Monitoring Extension
21st Feb 20239:31 amRNSDirector/PDMR Shareholding
8th Feb 20237:00 amRNS2023 Interim Results
19th Jan 20234:20 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.